Summary
Standard BioTools (LAB) Reports Q2 Loss, Tops Revenue Estimates
Standard BioTools (LAB) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.08 per share a year ago.
Standard BioTools Inc. (LAB) Q1 2025 Earnings Conference Call Transcript
Standard BioTools Inc. (NASDAQ:LAB ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants John Graziano - VP of IR Michael Egholm - President & CEO Alex Kim - CFO Conference Call Participants Kyle Boucher - TD Cowen Matt Stanton - Jefferies Paul Knight - KeyBanc Operator Good day and welcome to the Standard BioTools, Inc., First Quarter 2025 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded.
Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates
Standard BioTools (LAB) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.23 per share a year ago.
Labo Print S.A. Profile
| Health Care Technology Industry | Healthcare Sector | Michael Egholm CEO | WSE Exchange | PLLBPRT00013 ISIN |
| US Country | 814 Employees | - Last Dividend | - Last Split | 29 Jul 2003 IPO Date |
Overview
Standard BioTools Inc., previously known as Fluidigm Corporation until its name change in April 2022, is a significant player in providing comprehensive solutions for researchers and diagnostics labs across the globe. With its subsidiaries, it caters to a wide range of needs in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific regions. The company's operations are divided into two main segments: Proteomics and Genomics, offering a diverse range of advanced systems, consumables, reagents, and software services. Standard BioTools Inc. prides itself on enhancing research capacities in various fields such as academic institutions, clinical research laboratories, cancer centers, as well as biopharmaceutical and biotechnology companies, through its innovative product lineup. It leverages powerful license agreements with renowned institutions like the California Institute of Technology and Harvard University, underlining its commitment to cutting-edge research and technology.
Products and Services
Standard BioTools Inc. provides a robust suite of analytical systems, genomics solutions, and comprehensive services aimed at transforming research and clinical diagnostics. Key offerings include:
- CyTOF XT System: This advanced mass cytometry system automates high-parameter single-cell analysis by utilizing antibodies conjugated to metal isotopes. The CyTOF XT System offers unparalleled precision in analyzing cellular functions and populations, making it a critical tool for complex biological research.
- Hyperion XTi Imaging System: A pioneering instrument in spatial biology, the Hyperion XTi Imaging System delivers high-definition imaging of tissue microenvironments. This system allows researchers to visualize cellular interactions within tissues, providing insights into disease mechanisms and potential therapeutic targets.
- X9 Real-Time PCR System: Positioned as a next-generation real-time PCR analytical instrument, the X9 system incorporates innovative microfluidics technology through Integrated Fluidic Circuits (IFCs). This makes it ideal for fast, accurate genetic analysis and quantification, enhancing research in genomics workflows.
- IFC Controllers: Designed to seamlessly integrate with IFC formats, these controllers are essential for managing the precise fluidic operations needed for microfluidics-based genomic analysis, ensuring consistent performance and reliability in research processes.
- Biomark HD system: The Biomark HD offers unparalleled flexibility and sensitivity in real-time PCR analysis. Oriented for microfluidics-based workflows, this advanced analytical instrument suits various genomics applications, from single-cell analysis to large-scale studies, using prepared IFCs.
Contact Information
